2023 World Conference on Lung Cancer (Posters)-P2.10. Brain Metastases in Patients with Fusion-Positive Lung Cancers

Pdf Summary

The incidence of brain metastases (BrM) and its impact on outcomes in patients with fusion-positive lung cancers are not well reported. In this study, researchers identified patients with metastatic fusion-positive lung cancers using DNA-based sequencing. The baseline characteristics of patients with brain metastases at diagnosis and during treatment were recorded, and overall survival was assessed.<br /><br />The results showed that patients with fusion-positive lung cancers have a high risk of developing brain metastases. This highlights the importance of ongoing surveillance with brain imaging and the need for treatment strategies. It also emphasizes the necessity to develop targeted therapy agents with activity against brain metastases.<br /><br />The study included 438 patients in the cohort, with 181 patients having central nervous system (CNS) metastases and 257 patients without CNS metastases. The median age of patients was 59, and there was a roughly equal distribution of males and females. The majority of patients had a smoking history, with 68% being never smokers. The most common histology was non-squamous, and the most frequently observed gene fusions were ALK, ROS1, and RET.<br /><br />The study also analyzed the different types of brain metastases for each gene fusion. It was found that the incidence of brain metastases varied among the different gene fusions.<br /><br />The overall survival analysis showed that patients with brain metastases had a shorter median survival compared to those without brain metastases. However, the difference in survival was statistically significant only for patients with RET gene fusion.<br /><br />In conclusion, patients with fusion-positive lung cancers have a high risk of developing brain metastases. This study underscores the importance of monitoring for brain metastases and the need for targeted therapy agents with activity against CNS metastases. Future research should focus on developing effective treatments for patients with fusion-positive lung cancers and brain metastases.

Asset Subtitle

Jane Sui

Meta Tag

Speaker Jane Sui

Topic Metastatic NSCLC: Targeted Therapy - FUSIONS

Keywords

brain metastases

fusion-positive lung cancers

DNA-based sequencing

overall survival

surveillance

targeted therapy agents

gene fusions

ALK

ROS1

RET